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cal intervention, this study also seems to counter the ar- 
guments of people who oppose the use of sodium restric- 
tion to control blood pressure, i.e., that the large epide- 
miologic studies and meta-analyses of clinical trials are 
statistically invalid such that their demonstrations of an 
association can not be trusted. The fact that it worked in 
all of the subgroups studied suggests that a widespread 
application in the general population is warranted. 
The question that remains to be answered is whether 
or not this approach will translate well to the general popu- 
lation. Because the DASH diet and its low-sodium ver- 
sion were well tolerated in this study (as evidenced by the 
low dropout rate), there is hope that the people who adopt 
this approach could continue it. If they can continue to 
comply without the intense oversight that generally ac- 
companies a clinical intervention trial, there is evidence 
from studies of sodium restriction6 that the dietary ap- 
proach will likely continue to be successful. Still, this re- 
mains to be shown. As they design studies to evaluate 
this issue, the DASH study group might be wise to pay 
attention to the results of the nine National Cancer Insti- 
tute-funded “5-A-Day’’ interventions aimed at increas- 
ing the consumption of fruits and vegetables in various 
groups within the U.S. general population.’ Collectively, 
these studies show that one of the keys to successful 
dietary change is directed nutritional education through 
channels that provide a strong social support network 
(e.g., churches, schools, social organizations, and work- 
places). Another area that they might consider for future 
follow-up is to determine whether DASH or DASH-so- 
dium could be coupled with drug therapy to more effec- 
tively treat severe hypertension. This idea has precedent 
in the work of Siani et al.,” who showed that a diet high in 
potassium (reached through increased fruit and vegetable 
consumption) could reduce the amount and number of 
medications that one needs to control hypertension. Re- 
gardless of the future directions of the DASH research 
group, their work provides a strong argument in favor of 
nonpharmacologic alternatives (such as diet) to control 
high blood pressure. 
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Alcohol and Mortality: If You Drink, Do Not Forget Fruits and 
Veg e t a b I es 
Moderate amounts of alcohol may have quency, and accompanying lifestyle and eating 
cardioprotective effects. Several studies reported 
a higher protection by the consumption of wine. 
pattern. 
The favorable effects of wine have been attributed 
to differentpolYPhenolic compounds~ among 0th- 
Alcoholic beverages including wine have a long tradition 
as tmtential remedies and modulators of morbidity and 
ofwine2 and coronary artery disease risk; however, such a 
relationship was not found for beer3 or liquoflS5 Consump- 
tion. On the other hand, in the Canada Health Survey, 
light-to-moderate beer drinkers had a lower morbidity than 
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e ~ p e c t e d . ~  Contrary to the latter studies, several meta- 
analyses and studies concluded that the alcohol-related 
protection is independent of the type of alcohol."I0 In 
view of the potential protective effect of alcohol consump- 
tion, it is of general interest to clarify the question whether 
different alcoholic beverages elicit different effects on 
mortality. 
In a recent pooled prospective cohort study, the rela- 
tion between consumption of different types of alcoholic 
beverages and death from all causes, cancer, and coro- 
nary artery disease was published." In this study, data 
from three different population samples were pooled and 
a total of 13,064 men and 1 1,459 women were included in 
the final analysis. The different study samples were initi- 
ated and recruited between 1964 and 1976 and all partici- 
pants were followed up until 1995. At the baseline evalua- 
tion, total alcohol intake as well as alcohol intake accord- 
ing to beverage type was assessed. In addition, other 
lifestyle factors such as smoking habits, education level, 
leisure time physical activity, and body mass index were 
assessed, and the statistical analysis was adjusted for 
these parameters. Despite the large population and rather 
long follow-up, less than 1% of the participants were lost 
The analysis revealed a J-shaped curve for mortality 
and total alcohol consumption, as well as consumption of 
alcohol from wine." The consumption of one to seven 
drinks per week (1 drink defined as 12 g of alcohol) pro- 
duced a lower relative risk (RR) for all-cause mortality (RR 
0.82; 95% confidence interval [CI], 0.76-0.88) compared 
with nondrinkers. The intake of more than 35 drinks per 
week was associated with a nonsignificantly increased 
RR for all-cause mortality (RR 1.10; 95% CI, 0.95-1.26). 
Total alcohol intake was inversely related to coronary ar- 
tery disease death, and positively related to death from 
cancer. Light beer consumption (i.e., 1-7 drinks of beer/ 
week) had a small but significant effect on all-cause mor- 
tality (RR 0.90; CI 95%, 0.83-0.97) and on coronary artery 
disease risk (RR 0.78; 95% CI, 0.67-0.91). Light to moder- 
ate intake of wine seemed to have favorable effects on the 
RR for all-cause mortality. Light alcohol consumers avoid- 
ing wine had an RR for all-cause mortality of 0.90 (95% CI, 
0.82-0.99); however, light consumers drinking wine had a 
considerably lower all-cause mortality risk. Compared with 
light drinkers who avoided wine, those consuming 30% or 
less of their total alcohol in the form of wine had an RR for 
all-cause mortality of 0.67 (95% CI, 0.53-0.84); the RR for 
those consuming more than 30% of their alcohol intake in 
the form ofwine was 0.83 (95% CI, 0.74-0.93). The differ- 
ence between these two strata of wine consumers was not 
significantly different (P  = 0.15). Wine drinkers showed a 
significantly lower all-cause mortality risk than non-wine 
drinkers at all levels of consumption (P  <O.OOl). Cancer 
risk increased with increasing alcohol intake. Indepen- 
dent of the level of alcohol intake, non-wine drinkers had 
to follow-up. 
a higher cancer risk than wine drinkers. The consumption 
of small quantities of spirits had no significant effect on 
all-cause mortality risk or coronary artery disease. Higher 
quantities of spirit consumption led to an increase in RR 
for death from all causes, coronary artery disease, and 
cancer. 
The data from this Danish study offer additional sup- 
port for beneficial effects of light to moderate wine and 
beer consumption on all-cause mortality. Despite these 
positive results, the data from the present study have to 
be interpreted and implemented with caution. 
An important question in studies involving alcoholic 
beverages and disease risk is whether the effect is due to 
alcohol per se or if it is alcoholic beverage-specific. Al- 
though it has been reported that the effect of alcohol on 
risk of death including coronary artery disease risk is in- 
dependent of the type of b e ~ e r a g e , ~  several cross-sec- 
tional studies found only an inverse relationship between 
red wine consumption and the incidence of coronary ar- 
tery disease,12-14 and no protective effect was found for 
other alcoholic beverages, i.e., beer and spirits. The favor- 
able effects of wine have been attributed to its polyphe- 
nolic compounds such as flavonols, catechins, resveratrol, 
or a n t h o c y a n i n ~ . l ~ - ~ ~  In several epidemiologic studies, 
cardioprotective effects of flavonoids from dietary sources 
other than red wine have been o b ~ e r v e d . ' ~ - ~ ~  Most plant 
foods contain phenolic substances and the dietary intake 
of phenolic substances, depending on the composition of 
the diet, may be several hundreds of milligrams per day.15x2* 
It is often wrongly assumed that polyphenolic compounds 
are found in red wine but not in beer or other alcoholic 
beverages." As a function of the production process of 
alcoholic beverages, flavonoids are also found in beer. 
Indeed, beer may even be a more important source of fla- 
vonoids than certain red wines, although the variability of 
the content of phenolic acids in selected beers is very 
high.15 More than 60 different phenolic compounds have 
been identified in beer.I5 The concentration of phenolic 
acids in commercial beer depends mainly on the extent of 
their extraction during mashing. The concentration of 
polyphenols decreases owing to protein precipitation, 
especially during the processes of fermentat i~n '~ and fil- 
tration. As a general rule, it can be said that beer with 
turbidity usually has higher polyphenol content. 
Because polyphenolic compounds elicit a bitter taste 
and astringency, they are usually eliminated or at least 
reduced during food p r o c e s ~ i n g . ~ ~  Modem beer process- 
ing includes several filtration steps to eliminate turbidity, 
which leads to removal of most of the polyphenolic com- 
p o u n d ~ . ' ~  A highly processed beer is therefore a negli- 
gible source of flavonoids for the reasons stated above. If 
a beer contains flavonoids, they seem to be bioavailable;" 
however, whether the bioavailability is different from the 
bioavailability of red wine flavonoids is not known. The 
content of polyphenolics in red wine also show much vari- 
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ability as a function of many different factors such as the 
type of grape, origin, processing, and storage. Despite 
the polyphenol content of red wine, to what extent these 
polyphenolics are bioavailable is still controversial. In a 
recent paper, it was concluded that red wine is actually a 
poor source of bioavailable flavonols for humans.25 In the 
study by Gronbaek et al.” the consumption of one to 
seven drinks per week was associated with a favorable 
risk reduction, which would imply that the consumption 
of 1 drink per week would result in a favorable risk reduc- 
tion. The flavonol content of one glass of red wine would 
be negligible and hardly elicit a pharmacologic effect lead- 
ing to a measurable cardioprotective effect. Although red 
wine represents a potential source of polyphenolic com- 
pounds, other dietary sources such as tea, fruits, and veg- 
etables represent quantitatively more important 
sources.15.21 Accordingly, data about favorable effects of 
wine polyphenolics must be interpreted with caution.26 
This suggests that other mechanisms are responsible for 
the cardioprotective effects of red wine. 
Alcohol may elicit a cardioprotective effect through 
other mechanisms such as antithromobotic  effect^,^^-^^ 
effects on glucose tolerance,30 increased high-density li- 
poproteins (HDL),” inhibition of low-density lipoprotein 
oxidation,32 specific lipid effects such as cholesterol me- 
t a b ~ l i s m , ~ ~  ischemic pre~ondi t ioning,~~ or sedative ef- 
f e c t ~ . ~ ~  Despite many different proposed mechanisms, it 
remains unclear by which mechanism alcohol exerts it’s 
protective effect. In addition, neither ethanol nor red wine 
polyphenols affect mature atherosclerosis in an apolipo- 
protein E-deficient mice 
The drinking pattern in the present study differs from 
most other countries because most participants drank 
moderately or heavily on the weekends, and lightly dur- 
ing the week.“ It has been reported that the pattern of 
drinking in relation to food intake may explain some of the 
cardioprotective effects of alcohol in the form of wine. 
The Mediterranean lifestyle is characterized by consump- 
tion of wine with the main meals37.38 and it seems that 
alcohol may modulate postprandial metabolism fa~orably.~’ 
The mean age of the study population was greater 
than 50 years, more than 50% were smokers, the majority 
(approximately two-thirds) were physically inactive, and 
the mean body mass index (BMI, kg/m2) was 225.” These 
baseline characteristics reveal a rather high prevalence of 
the well known cardiovascular risk factors. Accordingly, it 
is not surprising that alcohol elicits a reduction in the 
relative risk of death because earlier studies showed that 
the protective effects of alcohol are especially seen in 
older subjects with multiple cardiovascular risk  factor^.^^.^^ 
This suggests that alcohol modulates the deleterious ef- 
fects of some cardiovascular risk factors favorably. 
There is controversy regarding whether differences 
exist in the modulation of all-cause mortality and coronary 
artery disease risk as a function of the beverage type. It is 
established, however, that there is a J-shaped relationship 
between all-cause mortality and alcohol intake.41 4 It is 
also very controversial as to where the nadir of the curve 
lies, i.e., at which consumption level is the lowest mortal- 
ity risk seen. The heterogeneity of subjects in epidemio- 
logic studies reflects the heterogeneity of the metabolic 
effects of alcohol in one individual compared with an- 
other. Recently, it was shown that cardiovascular risk 
might be modulated differently by alcohol as a function of 
the genetic make-up of alcohol dehydrogenase (ADH).46 
Hines et al.46 reported that subjects homozygous for the 
slow-oxidizing ADH (ADH3) do have higher HDL choles- 
terol levels and a substantially decreased risk of myocar- 
dial infarction. The cardioprotective effect of the ADH3 
polymorphism is caused by the slower rate of alcohol clear- 
ance, which is also associated with higher levels of HDL 
c h o l e ~ t e r o l . ~ ~  The amount of alcohol that provides the 
minimum risk for coronary artery disease varies consider- 
ably from one individual to the other according to the 
genetic make up ofthe alcohol metabolizing enzymes. Simi- 
larly, the level of alcohol consumption with the least all- 
cause mortality varies largely from one country to the 
other.41 Based on several studies, the pooled estimates of 
the nadir of alcohol intake (i.e., the level of alcohol con- 
sumption at which mortality is lowest) is 7.7 units of alco- 
hol per week for U.S. men (95% CI, 6.4-9.1).41 The corre- 
sponding number for U.S. women is 2.9 unitdweek (95% 
CI, 2.0-4.0); for U.K. men it is 12.9 unitdweek (95% Cl, 
10.8-15.1).41 These data do show the large variability of 
the amount of alcohol needed for beneficial andlor ad- 
verse effects. These data show that it may be very delete- 
rious to formulate recommendations of alcohol consump- 
tion for cardioprotection. 
Although alcohol represents an important modulator 
of cardiovascular risk, the effects may be largely due to 
characteristics of the consumer and less to chemicals as- 
sociated with a certain type of beverage andlor the alco- 
hol per se. There is insufficient evidence for a public health 
recommendation and justification of alcohol in any form 
for cardioprotection owing to the lack of large-scale pro- 
spective clinical trials, as discussed in a recent advisory 
statement of the American Heart A~sociation.~’ There is 
no “right” or “wrong” drink, therefore, but only a “right” 
or “wrong” amount and frequency of alcohol consump- 
t i ~ n . ~ *  It seems that if you ingest moderate amounts of 
wine (and probably any other alcoholic beverage), doing 
so in combination with a diet rich in fruits and vegetables 
would be a prudent way to elicit cardioprotective effects. 
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